| 2026-02-27 | -42.2% | earnings | GuruFocus.com | Fulgent Genetics Inc (FLGT) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges |
| 2026-02-27 | -42.2% | news | MT Newswires | Top Midday Decliners |
| 2026-02-27 | -42.2% | earnings | Seeking Alpha | Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix |
| 2026-02-27 | -42.2% | earnings | Seeking Alpha | Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript |
| 2026-02-27 | -42.2% | earnings | Seeking Alpha | Fulgent Genetics Non-GAAP EPS of $0.16 beats by $0.13, revenue of $83.3M misses by $2.08M |
| 2026-02-27 | -42.2% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-27 | -42.2% | earnings | Quiver Quantitative | FULGENT GENETICS ($FLGT) Releases Q4 2025 Earnings - Quiver Quantitative |
| 2026-02-27 | -42.2% | earnings | Investing.com | Earnings call transcript: Fulgent Genetics Q4 2025 beats EPS estimates, stock tumbles - Investing.com |
| 2026-02-27 | -42.2% | legal | TradingView | Fulgent Genetics, Inc. SEC 10-K Report - TradingView |
| 2026-02-27 | -42.2% | earnings | The Globe and Mail | Fulgent Genetics (FLGT) Earnings Transcript - The Globe and Mail |
| 2026-02-27 | -42.2% | news | Benzinga | 12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga |
| 2026-02-26 | -33.9% | earnings | Seeking Alpha | Fulgent Genetics Q4 2025 Earnings Preview |
| 2025-11-07 | +20.1% | earnings | Seeking Alpha | Fulgent Genetics raises 2025 revenue guidance to $325M as new products drive growth |
| 2025-11-07 | +20.1% | earnings | Seeking Alpha | Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript |
| 2025-11-07 | +20.1% | earnings | Seeking Alpha | Fulgent Genetics, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-11-07 | +20.1% | earnings | Seeking Alpha | Fulgent Genetics Non-GAAP EPS of $0.14 beats by $0.36, revenue of $84.07M beats by $2.64M |
| 2025-11-07 | +20.1% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-07 | +20.1% | earnings | Stock Titan | FLGT 8-K: Q3 2025 results press release and updated presentation - Stock Titan |
| 2025-11-06 | +16.7% | earnings | Seeking Alpha | Fulgent Genetics Q3 2025 Earnings Preview |
| 2025-05-01 | +16.2% | earnings | Seeking Alpha | Fulgent Genetics Q1 2025 Earnings Preview |
| 2023-08-04 | -15.8% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-05 | +14.2% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-11-03 | +12.9% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-05-02 | +12.5% | earnings | Seeking Alpha | Fulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathology |
| 2025-05-02 | +12.5% | earnings | Seeking Alpha | Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript |
| 2025-05-02 | +12.5% | earnings | Seeking Alpha | Fulgent Genetics rises on earnings, revenue beat |
| 2025-05-02 | +12.5% | earnings | Seeking Alpha | Fulgent Genetics beats top-line and bottom-line estimates; reaffirms FY25 outlook |
| 2025-05-02 | +12.5% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-05-02 | +12.5% | earnings | GuruFocus | Fulgent Genetics (FLGT) Q1 Earnings Surpass Expectations - GuruFocus |
| 2024-02-28 | -11.7% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-11-07 | -10.1% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-11-08 | -9.5% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-02 | -9.2% | news | Simply Wall St. | Fulgent Genetics (FLGT) Is Down 33.4% After 2025 Results And Oncology-Focused Expansion - What's Changed |
| 2026-03-02 | -9.2% | analyst | MT Newswires | UBS Adjusts Fulgent Genetics Price Target to $22 From $35, Maintains Buy Rating |
| 2026-03-02 | -9.2% | executive | Stock Titan | Fulgent Genetics (NASDAQ: FLGT) CFO has shares withheld for RSU taxes - Stock Titan |
| 2022-11-04 | -8.7% | legal | SEC EDGAR | FLGT 8-K: 5.02 (SEC Filing) |
| 2021-08-09 | -8.0% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-07-31 | +8.0% | earnings | Seeking Alpha | Fulgent Genetics Q2 2025 Earnings Preview |
| 2026-03-01 | -7.4% | earnings | Simply Wall St. | A Look At Fulgent Genetics (FLGT) Valuation After 2025 Results And 2026 Revenue Guidance |
| 2026-02-28 | -7.4% | earnings | Moby | Fulgent Genetics, Inc. Q4 2025 Earnings Call Summary |
| 2026-02-28 | -7.4% | news | The Globe and Mail | Fulgent Genetics Posts 2025 Results and 2026 Outlook - The Globe and Mail |
| 2026-02-28 | -7.4% | earnings | simplywall.st | Fulgent Genetics (FLGT) Loss Widening In Q4 2025 Tests Bullish Growth Narratives - simplywall.st |
| 2021-09-13 | -7.4% | news | The Motley Fool | Fulgent Genetics - FLGT - Stock Price & News - The Motley Fool |
| 2025-08-01 | +7.0% | earnings | Seeking Alpha | Fulgent Genetics lifts 2025 revenue outlook to $320M and narrows EPS loss guidance while advancing clinical pipeline |
| 2025-08-01 | +7.0% | earnings | Seeking Alpha | Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript |
| 2025-08-01 | +7.0% | earnings | Seeking Alpha | Fulgent Genetics, Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-01 | +7.0% | earnings | Seeking Alpha | Fulgent Genetics Non-GAAP EPS of $0.07 beats by $0.25, revenue of $81.8M beats by $5.59M |
| 2025-08-01 | +7.0% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-08-01 | +7.0% | earnings | Yahoo Finance | Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance |
| 2025-11-11 | +6.8% | news | Seeking Alpha | Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript |
| 2026-03-05 | +6.4% | earnings | Seeking Alpha | Fulgent Genetics, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2021-05-07 | -5.9% | earnings | The Motley Fool | Why Investors Loved Fulgent Genetics' Q1 Results - The Motley Fool |
| 2026-04-06 | -5.9% | news | Cổng thông tin điện tử tỉnh Lào Cai | Should I Buy Fulgent Genetics (FLGT) Stock in 2026 | Price at $16.69, Down 0.77% - Wall Street Picks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-05-09 | +5.2% | executive | simplywall.st | Here's Why It's Unlikely That Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Will See A Pay Rise This Year - simplywall.st |
| 2024-08-02 | +5.1% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-18 | +5.0% | legal | SEC EDGAR | FLGT 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-04-01 | +4.9% | legal | GlobeNewswire | FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire |
| 2026-04-01 | +4.9% | news | Cổng thông tin điện tử tỉnh Tây Ninh | FLGT Surges Ahead of Key Technical Level - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-03-12 | +4.9% | news | Seeking Alpha | Fulgent Genetics: A Major Market Misconception |
| 2026-03-12 | +4.9% | news | Seeking Alpha | Fulgent Genetics: A Major Market Misconception (NASDAQ:FLGT) - Seeking Alpha |
| 2022-08-03 | +4.7% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Fulgent Genetics (FLGT) - Zacks Investment Research |
| 2025-10-20 | +4.6% | legal | SEC EDGAR | FLGT 8-K: 8.01 and (SEC Filing) |
| 2022-08-04 | -4.6% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-01-12 | +4.5% | legal | SEC EDGAR | FLGT 8-K: 1.01 and (SEC Filing) |
| 2026-01-27 | -4.5% | news | Seeking Alpha | Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock |
| 2026-01-27 | -4.5% | news | Seeking Alpha | Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock - Seeking Alpha |
| 2024-02-21 | -4.3% | news | Seeking Alpha | Fulgent Genetics Stock: Buy Growth Ahead Below Liquidation Value (NASDAQ:FLGT) - Seeking Alpha |
| 2023-01-03 | +4.0% | legal | SEC EDGAR | FLGT 8-K: 5.02, 8.01 (SEC Filing) |
| 2022-04-18 | +3.7% | legal | SEC EDGAR | FLGT 8-K: 1.01, 2.02 (SEC Filing) |
| 2025-12-23 | -3.1% | M&A | Yahoo Finance | FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform - Yahoo Finance |
| 2024-11-19 | +3.0% | news | Yahoo Finance | Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance |
| 2022-02-07 | +2.9% | news | The Motley Fool | Why Fulgent Genetics Stock Plummeted 36.5% Last Month - The Motley Fool |
| 2025-12-22 | -2.7% | legal | SEC EDGAR | FLGT 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-12-22 | -2.7% | M&A | Stock Titan | AI-focused lab Fulgent expands into pathology with two acquisitions - Stock Titan |
| 2024-09-25 | -2.5% | earnings | Seeking Alpha | Fulgent Genetics: An NCAV Pick With Profit And Growth Potential (NASDAQ:FLGT) - Seeking Alpha |
| 2026-03-17 | +2.4% | M&A | MT Newswires | Fulgent Genetics Acquires Bako Diagnostics Assets, StrataDx for $56.9 Million |
| 2026-03-17 | +2.4% | M&A | Business Wire | Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx |
| 2026-03-17 | +2.4% | legal | SEC EDGAR | FLGT 8-K: 1.01, 2.01, 7.01 (SEC Filing) |
| 2026-03-17 | +2.4% | news | Stock Titan | Fulgent Genetics (NASDAQ: FLGT) buys Bako Diagnostics and StrataDx - Stock Titan |
| 2025-02-28 | -2.4% | earnings | Seeking Alpha | Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript |
| 2025-02-28 | -2.4% | earnings | Seeking Alpha | Fulgent Genetics Non-GAAP EPS of $0.04 beats by $0.16, revenue of $76M beats by $1.14M |
| 2025-02-28 | -2.4% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-05-06 | +2.4% | legal | SEC EDGAR | FLGT 8-K: 2.02 and (SEC Filing) |
| 2025-05-28 | +2.3% | legal | GlobeNewswire | INVESTIGATION ALERT: Edelson Lechtzin LLP Announces - GlobeNewswire |
| 2022-04-26 | -2.2% | legal | SEC EDGAR | FLGT 8-K: 2.01 and (SEC Filing) |
| 2025-06-23 | -2.2% | news | Seeking Alpha | Fulgent Genetics: A 'Sum Of The Parts' Story |
| 2025-06-23 | -2.2% | news | Seeking Alpha | Fulgent Genetics: A 'Sum Of The Parts' Story (NASDAQ:FLGT) - Seeking Alpha |
| 2025-07-17 | -2.0% | news | Seeking Alpha | Fulgent Genetics gets EU approval for germline sequencing system |
| 2025-03-20 | +1.9% | executive | Seeking Alpha | Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy |
| 2025-03-20 | +1.9% | executive | Seeking Alpha | Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy - Seeking Alpha |
| 2022-09-29 | +1.8% | legal | SEC EDGAR | FLGT 8-K: 5.02 (SEC Filing) |
| 2021-11-28 | -1.8% | news | TradingView | FLGT Stock Price and Chart — NASDAQ:FLGT - TradingView |
| 2023-02-28 | -1.8% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-31 | +1.5% | executive | Stock Titan | Fulgent Genetics (NASDAQ: FLGT) CEO cancels 750,000-share prepaid forward - Stock Titan |
| 2026-03-31 | +1.5% | executive | Stock Titan | Fulgent Genetics (NASDAQ: FLGT) CEO reports 30.7% ownership stake - Stock Titan |
| 2026-03-31 | +1.5% | news | Stock Titan | Fulgent Genetics (NASDAQ: FLGT) outlines 2026 meeting, pay and equity plan votes - Stock Titan |
| 2025-11-08 | +1.5% | earnings | simplywall.st | Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price Is Out Of Tune With Revenues - simplywall.st |
| 2022-06-30 | +1.4% | legal | SEC EDGAR | FLGT 8-K: 5.02 (SEC Filing) |
| 2026-01-08 | -1.2% | news | simplywall.st | Health Check: How Prudently Does Fulgent Genetics (NASDAQ:FLGT) Use Debt? - simplywall.st |
| 2025-09-08 | +1.2% | news | Seeking Alpha | Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy) |
| 2025-09-08 | +1.2% | news | Seeking Alpha | Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy) - Seeking Alpha |
| 2022-03-29 | +1.2% | legal | SEC EDGAR | FLGT 8-K: 5.02 and (SEC Filing) |
| 2024-05-03 | -1.1% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-02-23 | -1.0% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-10 | +1.0% | news | Stock Traders Daily | Precision Trading with Fulgent Genetics Inc. (FLGT) Risk Zones - Stock Traders Daily |
| 2022-05-03 | +0.9% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-16 | -0.9% | news | Business Wire | Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026 |
| 2026-04-16 | -0.9% | news | Stock Titan | Fulgent investors get first-quarter results and live Q&A on May 1 - Stock Titan |
| 2024-12-21 | +0.8% | news | Yahoo Finance | With 54% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing - Yahoo Finance |
| 2026-04-17 | -0.7% | legal | GlobeNewswire | Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - GlobeNewswire |
| 2026-04-17 | -0.7% | legal | Intellectia AI | Fulgent Genetics Under Investigation for Securities Law Violations - Intellectia AI |
| 2024-09-09 | -0.7% | news | Seeking Alpha | Fulgent Genetics: Core Growth Re-Acceleration As Critical Catalyst (NASDAQ:FLGT) - Seeking Alpha |
| 2025-12-02 | -0.7% | analyst | Seeking Alpha | Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating |
| 2025-12-02 | -0.7% | analyst | Seeking Alpha | Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating (NASDAQ:FLGT) - Seeking Alpha |
| 2026-01-30 | -0.7% | news | simplywall.st | Fulgent Genetics, Inc.'s (NASDAQ:FLGT) institutional investors lost 6.9% last week but have benefitted from longer-term gains - simplywall.st |
| 2024-12-24 | -0.6% | news | Seeking Alpha | Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside (NASDAQ:FLGT) - Seeking Alpha |
| 2025-01-15 | +0.5% | news | Moomoo | Fulgent Genetics (NASDAQ:FLGT Shareholders Incur Further Losses as Stock Declines 9.1% This Week, Taking Three-year Losses to 75% - Moomoo |
| 2024-02-12 | -0.3% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-04-18 | -0.3% | news | Cổng thông tin điện tử Tỉnh Sơn La | Fulgent Genetics (FLGT) Stock Pre Market (Momentum Building) 2026-04-18 - Top Picks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-23 | -0.3% | earnings | MarketBeat | Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Analysts - MarketBeat |
| 2026-04-22 | -0.1% | news | Business Wire | Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting |
| 2026-04-22 | -0.1% | news | Stock Titan | Head and neck cancer study from Fulgent gets ASCO oral slot - Stock Titan |
| 2021-11-09 | +0.0% | legal | SEC EDGAR | FLGT 8-K: 2.02, 7.01 (SEC Filing) |